Johan Waborg
Iconovo raises capital and reorganizes
Iconovo is raising capital of SEK 36,6 million and is simultaneously restructuring the organization with the aim of strengthening the commercial focus now...
Capital injection strengthens Iconovo
Iconovo is raising capital to continue...
Inhalation specialists Iconovo raises capital
An intranasal obesity treatment in development, a generic challenger...
Iconovo begins development of inhaled obesity treatment
Iconovo has filed a broad patent application for...
Iconovo begins 2024 with orders from leading pharmaceutical companies
Iconovo has received an order from one of...
Arcede moves on to stability study in collaboration with Iconovo
Lund-based Arcede Pharma continues to advance the project with...
Iconovo's CEO suspected of market manipulation
Iconovo recently announced that the company's CEO Johan Wäborg...
Interviews from LSX Nordic Congress
It's time again for LSX Nordic Congress,...
Iconovo welcomes Gerald Engström as principal owner through new share issue
Iconovo is conducting a private placement that will provide the company with...
Iconovo makes progress in the out-licensing process for ICOpre
Iconovo is approaching out-licensing of the ICOpre inhaler through...
Iconovo on the path to profitability
Iconovo, a leading developer of inhalation products, consolidates its...
Iconovo enters into partnership with Affilogic
Recently, Iconovo has entered into several...
Notes
Alligator Bioscience receives FDA approval for phase III mitazalimab dose
Lena Åredal appointed new CEO of SyntheticMR
BioArctic advances phase IIa study with exidavnemab
Novo Nordisk advances amycretin to Phase III
BioNTech acquires CureVac for $1,25 billion
NEWSLETTER
NEWS
AstraZeneca in billion-dollar deal in AI
Kancera rises on positive results from the KANDOVA study
New success strengthens Alzinova's licensing opportunities for ALZ-101
Upcoming events!
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
Bispecific and Chinese the new black in cancer
The venture capital cycle is complete – we are back where we started
